InvestorsHub Logo
Followers 0
Posts 484
Boards Moderated 0
Alias Born 10/10/2014

Re: None

Sunday, 09/09/2018 9:51:08 PM

Sunday, September 09, 2018 9:51:08 PM

Post# of 239
Good summary of current events:
https://seekingalpha.com/instablog/20587681-quadrant8/5208696-tocagen-riding-high-positive-momentum

Tocagen Riding High On Positive Momentum
Sep. 5, 2018 3:39 PM ET|About: Tocagen Inc (TOCA), Includes: AVXS, RGNX
Summary
Top analysts initiate Buy recommendations.

Another patient reporting Complete Response.

Expanding globally.

Top analysts initiate Buy recommendations


4-star rated Robyn Karnauskas from Citigroup initiated coverage on Tocagen Inc. (TOCA) with a Buy rating and a price target of $27.00 on September 4, 2018. She based her recommendation on the company’s innovative treatment approach.


5-star rated Gbola Amusa (Chardan Capital) initiated coverage of TOCA with a Buy rating and $30 price target on August 30, 2018. Mr. Amusa indicated that his rating was due to the following factors:


The initial Phase 1 study produced impressive and in some cases durable results in rHGG patients who otherwise die in eight to 11 months.

The risk-adjusted 2030 sales is $877.6 million for Toca 511 and Toca FC in HGGs.

BTD and PRIME designations for Toca 511 & Toca FC.


Tipranks reports that he has a 57% success rate and 27.4% average return per rating. It should be noted that back in November 2017 Mr. Amusa rated REGENXBIO (RGNX) as a Buy, when the stock was in the $20 range. The stock has since climbed to over $80 and currently sits at around $75. In December 2016, Mr. Amusa rated AveXis Inc (AVXS) as a Buy, when the stock was in the high $40 range. In April 2018, Novartis announced that it entered into an agreement to acquire AveXis Inc. for $8.7 billion ($218 per share).


Another patient reporting Complete Response


Tocagen’s latest presentation (August 2018) reports that in its Phase 1 Resection Study “6 responders received higher Toca 511 dose and are durable complete responders.” On Biden Cancer Initiative one patient (J.W.) is reporting that her husband enrolled in the Toca 5 clinical trial on December 2016, and “he’s doing amazing!” Additionally, she indicates that he “leads a completely normal life! Works full time.” In addition to this patient, other patients have also indicated that they are doing well and surviving long-term while in the Toca 5 clinical trial. While these data points are positive indications for Toca 511 & Toca FC, they are but a few data points and are not statistically significant.


Expanding globally


Tocagen’s latest presentation (August 2018) reports that the company will expand by:


Advance Toca 511 & Toca FC combined with SOC in newly diagnosed HGG - 2018

Define European regulatory path under PRIME designation - 2018

FPI for Toca 511 & Toca FC combined with SOC in newly diagnosed HGG - 2019

Advance European regulatory path under PRIME designation - 2019





Globally, Tocagen and ApolloBio entered into a license agreement (April 2018) to develop and commercialize Toca 511 & Toca FC in the greater China region.


Recently, Tocagen held pre-IND (Investigational New Drug) meetings with Japan’s PMDA (Pharmaceuticals and Medical Devices Agency).




With Tocagen expanding to other indications and regions, impressive patient results, and bullish analyst ratings, Tocagen is riding high on positive momentum.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent TOCA News